UCB (FRA:UNC0) Tariff Resilience Score: 7/10 (As of Jul. 14, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:UNC0 UCB SA FRA:UNC0
87 GF Score
Price €118.00
GF Value €112.24
Valuation Fairly Valued
View Full Analysis

What is UCB Tariff Resilience Score?

UCB FRA:UNC0 -4.84% 87 Tariff Resilience Score is 7 as of Jul. 14, 2026. GuruFocus rates FRA:UNC0 with a GF Score™ of 87/100 and a GF Value™ of €112.24 (Fairly Valued). Among 1,370 Biotechnology companies, UCB ranks better than 90.36% on this metric.

UCB has the Tariff Resilience Score of 7, which implies that the company might have Highly Resilient.

UCB has UCB SA has a diversified global supply chain and significant sales in Europe and the US. While exposed to tariffs, its strong R&D and product differentiation provide pricing power. Historical impacts from tariffs have been minimal due to strategic sourcing and manufacturing flexibility.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes UCB might have Highly Resilient.

UCB  (FRA:UNC0) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

UCB Tariff Resilience Score Related Terms

FRA:UNC0 vs VRTX, REGN, ALNY: Tariff Resilience Score Comparison

For the Biotechnology subindustry, UCB's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

UCB Tariff Resilience Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, UCB's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where UCB's Tariff Resilience Score falls into.


FRA:UNC0
87GF Score
UCB SA FRA:UNC0
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Tariff Resilience Score of 7 mean?
UCB (FRA:UNC0) has a Tariff Resilience Score of 7 as of Jul. 14, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, UCB ranks #132 out of 1370 companies in the Biotechnology industry, placing it in the top 9.6%.
Is UCB's Tariff Resilience Score too high?
UCB's current Tariff Resilience Score is 7. The Biotechnology industry median Tariff Resilience Score is 4.00. UCB's value of 7 is 75% above this industry median. Based on the distribution chart, UCB ranks #132 out of 1370 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, UCB has a GF Score™ of 87/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does UCB's Tariff Resilience Score compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, UCB ranks #132 out of 1370 companies for Tariff Resilience Score. This places UCB in the top 10% of its industry — outperforming the majority of peers. The industry median Tariff Resilience Score is 4.00. UCB's value of 7 is 75% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Biotechnology company?
The median Tariff Resilience Score among Biotechnology companies is 4.00, based on 1,370 companies in the industry. Companies in the top quartile (top 25%) have a Tariff Resilience Score significantly above this median, while those in the bottom quartile fall well below. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. UCB's current Tariff Resilience Score of 7 is 75% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. For the Biotechnology industry, the median Tariff Resilience Score is 4.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. UCB's current Tariff Resilience Score is 7. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is UCB stock overvalued right now?
Based on GuruFocus' analysis, UCB (FRA:UNC0) is currently considered Fairly Valued. The stock's GF Value™ is €112.24, compared to a current price of €118.00 — trading 5.1% above its estimated fair value. The current Tariff Resilience Score is 7 and 75% above the Biotechnology industry median of 4.00. UCB's overall GF Score™ is 87/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For UCB (FRA:UNC0), the current Tariff Resilience Score is 7 as of Jul. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is UCB (FRA:UNC0) Overvalued in 2026?

Based on GuruFocus' analysis, UCB stock appears to be overvalued. The current stock price of €118.00 is trading 5.1% above its estimated GF Value™ of €112.24. GuruFocus considers UCB to be Fairly Valued.

Key valuation signals for FRA:UNC0:

  • Tariff Resilience Score: 7
  • GF Value™: €112.24 vs. price of €118.00 (5.1% above fair value)
  • GF Score™: 87/100
  • Industry Position: 75% above the Biotechnology median (#132 of 1370)

No single metric tells the full story. See the FRA:UNC0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

UCB Business Description

Address Allee de la Recherche, 60, Brussels, BEL, B-1070
UCB is a Belgium-based biopharma firm focused on the development of novel therapies for the treatment of central nervous system and immunologic diseases. Historically, revenue was derived from allergy medicine Zyrtec and epilepsy drug Keppra, which have both lost patent protection. The firm's key products are Cimzia (immunology), Vimpat (epilepsy), Neupro (Parkinson's disease and restless leg syndrome), Briviact (epilepsy), Bimzelx (psoriasis), Evenity (osteoporosis), Nayzilam (cluster seizures), Fintepla (Dravet Syndrome and Lennox-Gastaut Syndrome), and Kygevvi (rare mitochondrial disease).
87GF Score

Get the complete analysis for FRA:UNC0

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€118.00
Price
€112.24
GF Value